See What HealthDay Can Do For You
Contact Us

Tamoxifen Use Tied to Diabetes Risk in Breast Cancer Survivors

But aromatase inhibitor use has no association with diabetes in older breast cancer survivors

FRIDAY, Sept. 30 (HealthDay News) -- Current tamoxifen therapy is associated with a significantly increased incidence of diabetes in older breast cancer survivors, according to a study published online Sept. 20 in Cancer.

Lorraine L. Lipscombe, M.D., from the Women's College Hospital in Toronto, and colleagues investigated whether tamoxifen treatment was associated with an increased risk of diabetes in 14,360 survivors of early-stage breast cancer who were older than 65 years. Participants were recruited between 1996 and 2006, and those diagnosed with diabetes during follow-up through March 31, 2008, were age-matched with up to five controls who did not develop diabetes. After adjusting for other risk factors, the risk of diabetes in current tamoxifen and aromatase inhibitor users was compared with non-users on the basis of prescriptions at diabetes diagnosis.

The investigators found that 10 percent of the patients were diagnosed with diabetes over a mean follow-up of 5.2 years. The risk of diabetes was significantly higher with current tamoxifen therapy versus no tamoxifen therapy (adjusted odds ratio, 1.24). Aromatase inhibitor therapy was not associated with diabetes.

"Current tamoxifen therapy is associated with an increased incidence of diabetes in older breast cancer survivors. These findings suggest that tamoxifen treatment may exacerbate an underlying risk of diabetes in susceptible women," the authors write.

Full Text (subscription or payment may be required)

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.